We have investigated the role of erythroid
transcription factors mRNA expression in patients with
acute myeloid leukemia (AML) in the context of cytogenetic and other prognostic molecular markers, such as
FMS-like Tyrosine Kinase 3 (FLT3),
Nucleophosmin 1 (NPM1), and CCAAT/enhance-
binding protein α (CEBPA) mutations. Further validation of Erythroid Krüppel-like Factor (
EKLF)
mRNA expression as a prognostic factor was assessed.We evaluated GATA
binding protein 1 (GATA1),
GATA binding protein 2 (GATA2),
EKLF and Myeloproliferative
Leukemia virus
oncogen homology (cMPL) gene
mRNA expression in the bone marrow of 65 AML patients at diagnosis, and assessed any correlation with NPM1, FLT3 and CEBPA mutations.
EKLF-positive AML was associated with lower WBC in peripheral blood (P = 0.049), a higher percentage of erythroblasts in bone marrow (p = 0.057), and secondary AMLs (P = 0.036). High expression levels of
EKLF showed a trend to association with T-cell
antigen expression, such as CD7 (P = 0.057). Patients expressing
EKLF had longer Overall Survival (OS) and Event Free Survival (EFS) than those patients not expressing
EKLF (median OS was 35.61 months and 19.31 months, respectively, P = 0.0241; median EFS was 19.80 months and 8.03 months, respectively, P = 0.0140). No correlation of GATA1, GATA2,
EKLF and cMPL levels was observed with FLT-3 or NPM1 mutation status. Four of four CEBPA mutated AMLs were
EKLF positive versus 10 of 29 CEBPA wild-type AMLs; three of the CEBPA mutated,
EKLF-positive AMLs were also GATA2 positive. There were no cases of CEBPA mutations in the
EKLF-negative AML group. In conclusion, we have validated
EKLF mRNA expression as an independent predictor of outcome in AML, and its expression is not associated with FLT3-ITD and NPM1 mutations.
EKLF mRNA expression in AML patients may correlate with dysregulated CEBPA.